Resumen

VIADA-GONZALEZ, Carmen et al. Evaluation of quality of life in patients with non-small cell lung cancer treated with CIMAvaxEGF® vaccine. Vaccimonitor [online]. 2021, vol.30, n.2, pp.69-80.  Epub 20-Mayo-2021. ISSN 1025-028X.

This report corresponds to quality of life analysis of patient with non-small cell lung cancer included in the phase III clinical trials Evaluation of CIMAvaxEGF® vaccine in lung cancer. The quality of life was evaluate using the EORTC questionnaires QLQ-C30 y QLQ-C13, at the beginning and every 3 months. To compare the median between two groups the Mann-Whitney non-parametric test was used. To compare the baseline and different follows times the Wilcoxon non-parametric test was used. The QLQ-C30 questionnaire showed a benefit in terms of the quality of life for the CIMAvaxEGF® vaccine group on the functional scores (global, role and social) and symptoms of the disease (pain). The QLQ-LC13 questionnaire showed a benefit in terms of the quality of life for the CIMAvaxEGF® vaccine group on the symptoms scores (dyspnea, dysphagia, alopecia and chest pain). It is noted as significant that the hemoptysis decreases in the group vaccinated as well as the dysphagia, the cough and the dyspnea observing a worsening in the control group.

Palabras clave : quality of life; non-small cell lung cancer; cancer vaccines; surveys and questionnaires; clinical trials.

        · resumen en Español     · texto en Español     · Español ( pdf )